An initial experiment with personalized antiplatelet therapy: The GRAVITAS trial

JAMA

Volumn 305, Issue 11, 2011, Pages 1136-1137

  Gurbel, Paul A ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

BLEEDING; BLOOD CLOTTING PARAMETERS; CAUSE OF DEATH; DRUG ELUTING STENT; DRUG MEGADOSE; EDITORIAL; GENOTYPE; HEART INFARCTION; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; THROMBOCYTE FUNCTION;

EID: 79952611488     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.332     Document Type: Editorial

References (12)

1. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345. (Pubitemid 38544175)
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908-2913. (Pubitemid 36736631)
3. Bonello L, Tantry US, Marcucci R, et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J AmColl Cardiol. 2010;56(12):919-933.
4. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-1105.
5. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-762.
6. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822-1834. (Pubitemid 350007957)
7. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
8. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor vs clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
9. Valgimigli M, Campo G, de Cesare N, et al; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation. 2009;119(25):3215-3222.
10. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404-1411. (Pubitemid 351447314)
11. Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160(1):16-22.e1.
12. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188-1199.